
Opinion|Videos|December 12, 2025
Understanding the FDA-Approved TYK2 Inhibitor in Psoriasis
It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!
Advertisement
Episodes in this series

Deucravacitinib, approved in 2022, was the first selective TYK2 inhibitor for moderate-to-severe psoriasis. Can you describe its mechanism of action?
What are your impressions of the recently published long-term data for deucravacitinib in plaque psoriasis, which demonstrated sustained efficacy and a consistent safety profile through five years of treatment?
How does this data influence your perception of its role in long-term disease management?
Which patients are ideal candidates for deucravacitinib?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5



























































